SAMANTHA CHANEL POTENCIANO: Open Payments
NPI 1821722943 · RENO, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,159 in 55 payments from 12 companies in 2025. Trend: 2023 $945 · 2024 $951 · 2025 $1,159
Food & beverage: $1,159
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 31 | $527 |
| Madrigal Pharmaceuticals | 6 | $221 |
| QOL Medical, LLC | 4 | $99 |
| Aimmune Therapeutics, Inc. | 3 | $62 |
| Janssen Biotech, Inc. | 3 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $42 |
| Novo Nordisk Inc | 1 | $40 |
| Lilly USA, LLC | 1 | $32 |
| Gilead Sciences, Inc. | 1 | $30 |
| GENZYME CORPORATION | 1 | $25 |
Products named: RINVOQ, REZDIFFRA, LINZESS, Sucraid, SKYRIZI, TREMFYA, DUPIXENT, VOWST.
Industry payments across NV — which companies pay providers there.
